Skip to main content
Springer Nature Link
Log in

Chemotherapy for Seminoma

  • Chapter
Carcinoma of the Kidney and Testis, and Rare Urologic Malignancies

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 171 Accesses

Abstract

Testicular germ cell tumors represent only about 1%–2% of all human malignant tumors; however, they are the most common malignancies in young adult men. The vast majority of patients with disseminated germ cell tumors are curable with the currently available combination chemotherapy regimens. These results are in contrast to those obtained with chemotherapy for other disseminated malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Amato RJ, Ellerhorst J, Banks M, Logothetis CJ (1995) Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer 31A: 2223–2228

    Article  Google Scholar 

  • Bajorin DF, Sarosdy MF, Pfister DG, et al. (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598–606

    PubMed  CAS  Google Scholar 

  • Beyer J, Kramar A, Mandanas R (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14: 2638–2645

    PubMed  CAS  Google Scholar 

  • Beyer J, Kingreen D, Krause M, et al. (1997) Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79: 161–168

    Article  PubMed  CAS  Google Scholar 

  • Bosl GJ, Geller NL, Bajorin D, et al. (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6: 1231–1238

    PubMed  CAS  Google Scholar 

  • Chou T-C, Motzer RJ, Tong Y, et al. (1994) Computerized quantification of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517–1524

    Article  PubMed  CAS  Google Scholar 

  • Culine S (1996) Optimal management of residual mass after chemotherapy in advanced seminoma: there is a time for everything. J Clin Oncol 14: 2884–2885

    PubMed  CAS  Google Scholar 

  • Farhat F, Culine S, Théodore C, et al. (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 77: 1193–1197

    Article  PubMed  CAS  Google Scholar 

  • Fossa SD, Droz JP, Stoter G, et al. (1995) Cisplatin, vincristine and ifosfamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. Br J Cancer 71: 619–624

    Article  PubMed  CAS  Google Scholar 

  • Guillou L, Estreicher A, Chaubert P, et al. (1996) Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 149: 1221–1228

    PubMed  CAS  Google Scholar 

  • Horwich A, Dearnaley DP, A’Hern R, et al. (1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A: 1307–1310

    Article  Google Scholar 

  • McCaffrey JA, Mazumdar M, Bajorin DF, et al. (1997) Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559–2563

    PubMed  CAS  Google Scholar 

  • Mead et al., International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603

    Google Scholar 

  • Mencel PJ, Motzer R, Mazumdar M, et al. (1994) Advanced seminoma: treatment results, survival, and prognostic fac-tors in 142 patients. J Clin Oncol 12: 120–126

    PubMed  CAS  Google Scholar 

  • Motzer RJ (1996) Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotheraphy. J Clin Oncol 14: 2625–2626

    PubMed  CAS  Google Scholar 

  • Motzer RJ, Mazumdar M, Bosl GJ (1996) High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098–1105

    PubMed  CAS  Google Scholar 

  • Nichols CR (1996) Ifosfamide in the treatment of germ-cell tumors. Semin Oncol 23: 65–73

    PubMed  CAS  Google Scholar 

  • Peckham MJ, Barret A, McElwain TJ, Hendry WF (1979) Com¬bined management of malignant teratoma of the testis. Lancet 11: 267–270

    Article  Google Scholar 

  • Puc HS, Heelan R, Mazumdar M, et al. (1996) Management of residual mass in advanced seminoma: results and recom-mendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14: 45–460

    Google Scholar 

  • Roth BJ (1996) The role of ifosfamide in the treatment of testicular and urothelial malignancies. Semin Oncol 23: 19–27

    PubMed  CAS  Google Scholar 

  • Schmoll HJ, Harstrick A, Bokemeyer C, et al. (1993) Single- agent carboplatin for advanced seminoma. Cancer 72: 237–243

    Article  PubMed  CAS  Google Scholar 

  • Sleijfer DT, Mulder NH (1997) Treatment of advanced semi-noma: an update. Anticancer Drugs 8: 107–112

    Article  PubMed  CAS  Google Scholar 

  • Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14: 1637–1641

    PubMed  CAS  Google Scholar 

  • Warren GP, Einhorn LH (1995) Gallium scans in the evalua¬tion of residual masses after chemotherapy for seminoma. J Clin Oncol 13: 2784–2788

    PubMed  CAS  Google Scholar 

  • Williams SD, Birch R, Einhorn LH, et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440

    Article  PubMed  CAS  Google Scholar 

  • Xian H, Mazumdar M, Bajorin DF, et al. (1997) Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15: 2553–2558

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University Hospitals Gasthuisberg, Catholic University of Leuven, Herestraat 49, B-3000, Leuven, Belgium

    H. Dumez MD (Resident) & A. Van Oosterom MD, PhD (Professor and Chairman)

Authors
  1. H. Dumez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Van Oosterom MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology Kenneth Norris Jr. Cancer Hospital and Research Institute, University of Southern California School of Medicine, 1441 Eastlake Avenue, 90033-004, Los Angeles, CA, USA

    Zbigniew Petrovich MD, FACR (Professor of Radiation Oncology and Urology Chairman) (Professor of Radiation Oncology and Urology Chairman)

  2. Department of Urology, Catholic University of Leuven, University Hospitals Gasthuisberg, 49, Herestraat, B-3000, Leuven, Belgium

    Luc Baert MD, PhD (Professor and Chairman) (Professor and Chairman)

  3. Hylda Cohn/American Cancer Society, USA

    Luther W. Brady MD (Professor of Clinical Oncology, and Professor) (Professor of Clinical Oncology, and Professor)

  4. Department of Radiation Oncology, Allegheny University of the Health Sciences Allegheny University Hospitals, Hahnemann Broad & Vine Sts., Mail Stop 200, Philadelphia, PA, 19102-1192, USA

    Luther W. Brady MD (Professor of Clinical Oncology, and Professor) (Professor of Clinical Oncology, and Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dumez, H., Van Oosterom, A. (1999). Chemotherapy for Seminoma. In: Petrovich, Z., Baert, L., Brady, L.W. (eds) Carcinoma of the Kidney and Testis, and Rare Urologic Malignancies. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59839-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59839-5_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64144-2

  • Online ISBN: 978-3-642-59839-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics